Dr. Agarwal's Q4 profit jumps 52%, but the numbers were already priced in.
Consolidated PAT hit ₹168 cr in Q4, a 52.4% YoY jump. Total income for the quarter was ₹2,125 cr.
— 4 earlier stories on Dr. Agarwal's Health Care Ltd. →What's new
- Q4 consolidated PAT rose 52.4% YoY to ₹168 cr, outpacing both revenue and EBITDA growth.
- FY26 total income hit ₹2,125 cr, up 20.9% YoY; EBITDA grew 22.2% to ₹614 cr.
- Board approved shifting ₹14.88 cr in unspent IPO expenses to general corporate purposes.
Why this matters
The 52.4% profit surge is sharp, but it's largely a low-base effect from the prior-year quarter. The ₹14.88 crore in unspent IPO money being freed for inorganic moves is a procedural signal, not a material shift for a company with a ₹14,997 crore market cap.
What we're watching
- Whether the company announces its first inorganic deal using the reallocated IPO funds.
- How the profit growth translates in FY27, now that the low base fades.
- Any update on the margin trajectory, given the divergence between revenue (20.9%) and PAT (52.4%) growth.
The full read
Dr. Agarwal's Health Care posted a Q4 profit of ₹168 crore, up 52.4% year-on-year. Revenue grew 20.9% to ₹2,125 crore for the full year, while EBITDA climbed 22.2% to ₹614 crore. The profit surge outpaces the top line, pointing to operating effects from the company's model. But the numbers were expected. For a ₹14,997 crore market-cap company, the real move is small: ₹14.88 crore in unspent IPO expenses are now freed up for inorganic bets. That's a tiny war chest, but it's the first public signal the company is ready to buy.
Questions answered
- What drove the sharp 52.4% jump in Q4 profit?
- The growth is largely a low-base effect from the prior-year quarter. While revenue grew 20.9% and EBITDA grew 22.2%, profit grew faster because of operating effects and a lower tax or interest burden in the quarter.
- What is the company planning with the ₹14.88 crore in IPO money?
- The board approved reallocating unspent IPO issue expenses to general corporate purposes and 'unidentified inorganic acquisitions.' This means the cash can now be used for deals, though none are announced.
- Are these earnings new information for the market?
- The analyst rationale states the results were 'likely anticipated by the market given prior guidance and industry trends.' This is a standard earnings release for a widely followed mid-cap stock, so the numbers should be largely priced in.
- What is Dr. Agarwal's market size?
- The company's market capitalization is ₹14,997 crore, making it a mid-cap in the healthcare space.
Dr. Agarwal's Health Care Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on AGARWALEYE →- 21 May 2026 · 6:08 PM IST Dr. Agarwal's Q4 profit jumps 52%, but the numbers were already priced in.
- 40d ago Dr. Agarwal's Health Care Q4 transcript adds no new data
- 46d ago Dr. Agarwal's Health Care reports FY26 revenue of over ₹2,000 cr
- 46d ago Dr. Agarwal's profit jumps 52% on 21% revenue growth
- 46d ago Dr. Agarwal's Health Care lifts PAT 52% on 22% revenue growth